

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-38 (Cancelled).

39 (Currently Amended). A method for treatment of a psychiatric disorder, disease or condition selected from the group consisting of post-traumatic stress disorder (PTSD), depression, bipolar disorder and schizophrenia and related disorders, which comprises administering to an individual in need of such a treatment an effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

40 (Currently Amended). ~~A~~ The method according to claim 39, wherein said administering step comprises immunizing said individual ~~is immunized with a therapeutically effective amount of an~~ said agent selected from the group consisting of ~~(i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).~~

41 (Currently Amended). The method according to claim 39, wherein said agent is Copolymer 1.

42 (Currently Amended). The method according to claim 39, wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

43 (Withdrawn/Currently Amended). The method according to claim 39, wherein said agent is T cells which have been activated by Copolymer 1.

44 (Cancelled).

45 (Currently Amended). ~~A~~ The method according to claim ~~44~~ 39, wherein said psychiatric anxiety disorders ~~disorder, disease or condition include phobic disorders, obsessive compulsive disorder, stress, is post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder.~~

46 (Currently Amended). ~~A~~ The method according to claim ~~45~~ 39, wherein said psychiatric anxiety disorder, disease or condition is post-traumatic stress disorder (PTSD) and said agent is Copolymer 1.

47 (Currently Amended). ~~A~~ The method according to claim ~~44~~ 39, wherein said psychiatric mood disorders ~~disorder, disease or condition include~~ is selected from the group consisting of ~~depression, dysthymic disorder, and bipolar disorders and cyclothymic disorder.~~

48 (Currently Amended). ~~A~~The method according to claim ~~44~~39, wherein said psychiatric disorder, disease or condition is schizophrenia and said agent is Copolymer 1.

49 (Currently Amended). ~~A~~The method according to claim ~~44~~39, wherein said schizophrenia related disorders include brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder.

50 - 51 (Cancelled).

52 (Currently Amended). ~~A~~The method according to claim 41, wherein the Copolymer 1 is administered in the form of a vaccine.

53 (Currently Amended). ~~A~~The method according to claim 52, wherein said vaccine comprises Copolymer 1 without an adjuvant.

54 (Currently Amended). ~~A~~The method according to claim 52, wherein said vaccine comprises Copolymer 1 emulsified in an adjuvant suitable for human clinical use.

55 (Currently Amended). ~~A~~The method according to claim 54, wherein said adjuvant is aluminum hydroxide, aluminum hydroxide gel or aluminum hydroxyphosphate.